Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SYN007
MIFTS: 54

Synovitis

Categories: Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Synovitis

About this section

MalaCards integrated aliases for Synovitis:

Name: Synovitis 12 74 52 54 6 15 17 71

Classifications:

MalaCards categories:
Global: Rare diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2703
MeSH 43 D013585
NCIt 49 C50766
SNOMED-CT 67 416209007
UMLS 71 C0039103
Sources

Summaries for Synovitis

About this section
Disease Ontology : 12 A connective tissue disease that results in inflammation located in synovial membrane that lines a synovial joint which causes pain and swelling.

MalaCards based summary : Synovitis is related to blau syndrome and sapho syndrome, and has symptoms including arthralgia, myalgia and metatarsalgia. An important gene associated with Synovitis is RELN (Reelin), and among its related pathways/superpathways are Innate Immune System and Integrin Pathway. The drugs Etanercept and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include synovial membrane, bone and t cells, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 74 Synovitis is the medical term for inflammation of the synovial membrane. This membrane lines joints that... more...

Sources

Related Diseases for Synovitis

About this section

Diseases related to Synovitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 878)
# Related Disease Score Top Affiliating Genes
1 blau syndrome 33.9 TNF IL1RN IL1B
2 sapho syndrome 33.5 TNF IL1RN IL18 CXCL8
3 tenosynovitis 31.5 TNF IL6 IL1RN CRP
4 bursitis 31.5 TNF IL1B CRP
5 juvenile arthritis 31.4 IL6 CXCL8 CRP
6 gout 31.3 TNF IL6 IL1B IL18 CXCL8
7 hemophilic arthropathy 31.3 TNFSF11 COMP
8 chondrocalcinosis 31.2 MMP3 MMP1 IL1RN IL1B
9 septic arthritis 31.2 TNF MMP3 MMP1 IL6 IL1B CXCL8
10 osteomyelitis 31.2 TNFSF11 TNF IL6 IL1RN IL1B CXCL8
11 osteonecrosis 31.1 TNFSF11 TNF IL1B COL2A1
12 temporal arteritis 31.1 TNF IL6 IL1RN IL1B CRP
13 spondylarthropathy 31.1 TNF COL2A1 CD163
14 spondylitis 31.0 TNFSF11 TNF IL6 IL1RN CRP
15 carpal tunnel syndrome 31.0 IL6 IL1RN IL1B
16 pustulosis of palm and sole 30.9 TNF IL1RN CXCL8 CRP
17 reactive arthritis 30.9 TNF IL6 IL1B CXCL8 CRP COMP
18 ankylosis 30.9 TNFSF11 TNF CRP
19 rheumatoid arthritis 30.9 VCAM1 TNFSF11 TNF MMP3 MMP13 MMP1
20 spondyloarthropathy 1 30.8 TNFSF11 TNF MMP3 IL1RN CRP CD163
21 spondyloarthropathy 30.7 VCAM1 TNFSF11 TNF MMP3 IL6 IL1B
22 bone resorption disease 30.7 TNFSF11 TNF IL6 IL1B CRP
23 vasculitis 30.7 VCAM1 TNF IL6 ICAM1 CRP
24 uveitis 30.7 TNF IL6 IL1B ICAM1 CXCL8
25 leprosy 3 30.7 TNF IL6 IL1B CXCL8
26 syphilis 30.7 TNF IL6 CRP
27 juvenile rheumatoid arthritis 30.7 TNF MMP3 IL6 IL1RN IL1B IL18
28 lyme disease 30.7 TNF IL6 IL1B IL18 CRP
29 pertussis 30.7 TNF IL6 IL1B CXCL8
30 psoriatic arthritis 30.6 TNFSF11 TNF MMP3 MMP1 IL6 IL1RN
31 cryoglobulinemia 30.6 TNF IL6 IL1B
32 psoriasis 30.6 VCAM1 TNF IL6 IL1B IL18 ICAM1
33 rubella 30.6 IL1B TNF IL6
34 systemic scleroderma 30.6 TNF IL6 IL1B CRP
35 sarcoidosis 1 30.6 TNF IL1RN IL1B IL18 ICAM1 CRP
36 iridocyclitis 30.5 TNF IL6 CRP
37 myositis 30.5 TNF IL6 IL1B CXCL8
38 brucellosis 30.5 TNF IL6 IL1RN IL18 CXCL8 CRP
39 angioimmunoblastic lymphadenopathy with dysproteinemia 30.5 TNF IL6
40 congestive heart failure 30.5 TNF IL6 IL1B CRP
41 dermatitis 30.5 TNF IL6 IL1B IL18 CXCL8
42 cellulitis 30.4 TNF IL6 IL1B CRP
43 allergic hypersensitivity disease 30.4 VCAM1 TNF ICAM1 CXCL8
44 exanthem 30.4 TNF IL6 IL1RN IL1B CXCL8 CRP
45 rheumatoid vasculitis 30.4 VCAM1 TNF ICAM1
46 crohn's disease 30.4 TNF IL6 IL1B IL18 CXCL8 CRP
47 familial mediterranean fever 30.4 TNF IL6 IL1RN IL1B IL18 CXCL8
48 salmonellosis 30.3 TNF IL6 IL1B IL18
49 lepromatous leprosy 30.3 TNF IL18 ICAM1
50 chikungunya 30.3 TNF IL6 IL1B IL18

Graphical network of the top 20 diseases related to Synovitis:



Diseases related to Synovitis
Sources

Symptoms & Phenotypes for Synovitis

About this section

UMLS symptoms related to Synovitis:


arthralgia, myalgia, metatarsalgia

MGI Mouse Phenotypes related to Synovitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 CD163 COL2A1 COMP CRP ICAM1 IL18
2 growth/size/body region MP:0005378 10.25 COL2A1 COMP ICAM1 IL18 IL1B IL1RN
3 cardiovascular system MP:0005385 10.23 CD163 COL2A1 COMP CRP ICAM1 IL18
4 immune system MP:0005387 10.22 CD163 CD68 COL2A1 COMP CRP ICAM1
5 hematopoietic system MP:0005397 10.18 CD163 CD68 ICAM1 IL18 IL1B IL1RN
6 integument MP:0010771 9.91 ICAM1 IL18 IL1B IL1RN IL6 MMP13
7 muscle MP:0005369 9.76 CD163 COMP ICAM1 IL18 IL6 RELN
8 skeleton MP:0005390 9.7 CD68 COL2A1 COMP IL1B IL1RN IL6
9 vision/eye MP:0005391 9.28 CD163 COL2A1 ICAM1 IL18 IL6 LTB
Sources

Drugs & Therapeutics for Synovitis

About this section

Drugs for Synovitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4 185243-69-0
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Infliximab Approved Phase 4 170277-31-3
8
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
9
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
10
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
11
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
12
Chromium Approved Phase 4 7440-47-3 27668
13
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
15
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
16 Pharmaceutical Solutions Phase 4
17 Vitamins Phase 4
18 Hormones Phase 4
19 Methylprednisolone Acetate Phase 4
20 Respiratory System Agents Phase 4
21 Anti-Asthmatic Agents Phase 4
22 Cyclosporins Phase 4
23 Antifungal Agents Phase 4
24 Anti-Infective Agents Phase 4
25 Calcineurin Inhibitors Phase 4
26 Calciferol Phase 4
27 Adrenocorticotropic Hormone Phase 4
28 Melanocyte-Stimulating Hormones Phase 4
29 beta-Endorphin Phase 4
30 Calcium, Dietary Phase 4
31 Trace Elements Phase 4
32
Nickel Phase 4 7440-02-0 934
33 Nutrients Phase 4
34 Micronutrients Phase 4
35
Calcium Nutraceutical Phase 4 7440-70-2 271
36
Abatacept Approved Phase 3 332348-12-6 10237
37
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
38
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
39
Hydroxychloroquine Approved Phase 3 118-42-3 3652
40
Sulfasalazine Approved Phase 3 599-79-1 5353980 5359476
41
Certolizumab pegol Approved Phase 3 428863-50-7
42
Colchicine Approved Phase 3 64-86-8 2833 6167
43
Zoledronic Acid Approved Phase 3 118072-93-8 68740
44
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
45
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
46
Ketorolac Approved Phase 3 66635-83-4, 74103-06-3 3826
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
48
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
49
Chondroitin Phase 3 9007-27-6 53477707
50 Interleukin 1 Receptor Antagonist Protein Phase 3

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis Unknown status NCT02437461 Phase 4 Triamcinolone hexacetonide
2 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
3 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
4 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
5 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
6 Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone Completed NCT00396747 Phase 4 Infliximab, methylprednisolone, methotrexate;Methotrexate;Methotrexate + Methylprednisolone;Methotrexate + Infliximab
7 Combination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis. Completed NCT00209859 Phase 4 Methotrexate;Intraarticular betamethasone;Cyclosporine/placebo-cyclosporine
8 Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis. Completed NCT00502853 Phase 4 rituximab [MabThera/Rituxan];Methotrexate
9 Phase 4 Study of Low Dose Prednisolone for Knee Osteoarthritis Completed NCT01619163 Phase 4 Placebo;Prednisolone
10 Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab Completed NCT01717859 Phase 4 Tocilizumab
11 Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging Completed NCT01948388 Phase 4 corticotrophin 80 units
12 A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs Completed NCT01034397 Phase 4 tocilizumab [RoActemra/Actemra];placebo;non-biological DMARDs
13 Aiming for Remission in Rheumatoid Arthritis: a Randomized Trial Examining the Benefit of Ultrasonography in a Clinical TIght Control Regimen Completed NCT01205854 Phase 4
14 A Multicentre Randomised Trial Of Etanercept And Methotrexate To Induce Remission In Early Inflammatory Arthritis Completed NCT01303874 Phase 4 Etanercept (ETN);Placebo
15 Randomized Clinical Evaluation of Bone Mineral Density Changes Under Non-cemented Trabecular Metal Tibial Component and Cemented Titanium Controls. Completed NCT01764984 Phase 4
16 Can Bone Erosions Heal in Adalimumab (Humira) Treated Rheumatoid Arthritis Patients. An Imaging Study Using Computed Tomography and Magnetic Resonance Imaging. Completed NCT00696059 Phase 4 Adalimumab (Humira)
17 Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia. Completed NCT03369379 Phase 4 D3 Vitamin
18 Use of Acthar in Rheumatoid Arthritis Related Flares Recruiting NCT02541955 Phase 4 Acthar
19 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) Active, not recruiting NCT03419650 Phase 4 ACTHar
20 Serum Calprotectin Level in Patients With Rheumatoid Arthritis and Osteoarthritis Not yet recruiting NCT04201886 Phase 4
21 Adipose Derived Stromal Cell Transplantation as an Adjunct to Arthroscopy in Treatment of Effusion Synovitis of the Early Degenerative Knee Not yet recruiting NCT03922490 Phase 4
22 Effect of Nickel Sensitivity on Patient Reported Outcomes After Total Knee Arthroplasty Not yet recruiting NCT04058743 Phase 4
23 Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs Withdrawn NCT01878318 Phase 4 methotrexate;tocilizumab [RoActemra/Actemra]
24 Multicentre Canadian Study to Measure the Safety and Efficacy of Synoviorthesis Performed With Yttrium-90 or Rhenium-186 Sulfide Unknown status NCT01615991 Phase 3 Radiosynoviorthesis
25 Ultrasound Scores as Imaging Biomarkers of Early Response to Subcutaneous Tocilizumab in Association With Methotrexate in Very Early Rheumatoid Arthritis (TOVERA) Unknown status NCT02837146 Phase 3 Methotrexate (MTX)
26 A Phase 3, Multicenter, Randomized, Open, Prospective, Controlled, Parallel Group Study of Reduction of Therapy in Patients With Rheumatoid Arthritis in Ongoing Remission. Unknown status NCT02779114 Phase 3 Control group
27 Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee Completed NCT00604539 Phase 3 Chondroitin sulphate (Condrosan);Placebo
28 Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis Completed NCT00522184 Phase 3
29 The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients Completed NCT01213017 Phase 3 certolizumab pegol
30 A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate Completed NCT00420199 Phase 3 Abatacept;Placebo
31 An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target Completed NCT02566967 Phase 3 tofacitinib
32 A 16-week Double-blind, Placebo-controlled (for Initial 2 Weeks) Randomized Period, Followed by a 24-week Open-label Extension to Assess Magnetic Resonance Image (MRI) - Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) Completed NCT01235598 Phase 3
33 Open Label, Multicentric Phase IIIb Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Dedicated Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis (RA) Completed NCT00996606 Phase 3 DMARDs;Tocilizumab
34 DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)? Completed NCT02164214 Phase 3 etanercept Treatment
35 A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever Completed NCT01705756 Phase 3 Kineret
36 Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis Completed NCT01748084 Phase 2, Phase 3 Rituximab;Placebo (NaCl)
37 A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis Recruiting NCT02662985 Phase 3 AIN457 (secukinumab);Placebo
38 A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis Recruiting NCT04303026 Phase 3 Zoledronic Acid;Saline 0.9%
39 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath Active, not recruiting NCT02371369 Phase 3 Pexidartinib;Placebo
40 A Phase 3, Multicenter, 12-Week, Double-Blind and 40-Week Open Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Knee Not yet recruiting NCT03081806 Phase 3 X0002
41 A Double-blinded, Prospective, Randomized, Controlled Trial Comparing Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders Terminated NCT02266433 Phase 3 Ketorolac;Dexamethasone
42 Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial Unknown status NCT02594878 Phase 2 Pamidronatdinatrium
43 A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) Completed NCT01643850 Phase 2 MCS110;Placebo
44 A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties Completed NCT01272830 Phase 2 Placebo;Apatone®B
45 A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis Completed NCT02087904 Phase 2
46 Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Completed NCT01261429 Phase 2 Tasigna
47 Evaluation of Inflammatory and Structural Joint Damage in Patients With Psoriasis and Psoriatic Arthritis Treated With Secukinumab: A Phase 2, Single Arm, Single Centre Mode of Action Study (Psoriasis-Arthritis & Bone Program, PSARTROS) Completed NCT02483234 Phase 2 secukinumab
48 Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence Completed NCT00678782 Phase 2 etanercept;placebo
49 Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy Completed NCT00001677 Phase 2 Methotrexate;Fludarabine
50 Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study Completed NCT00506896 Phase 2 intraarticular injection

Search NIH Clinical Center for Synovitis

Sources

Genetic Tests for Synovitis

About this section
Sources

Anatomical Context for Synovitis

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Synovitis:

19
Synovial Membrane

MalaCards organs/tissues related to Synovitis:

40
Bone, T Cells, Bone Marrow, Endothelial, Neutrophil, Testes, B Cells
Sources

Publications for Synovitis

About this section

Articles related to Synovitis:

(show top 50) (show all 10794)
# Title Authors PMID Year
1
Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides. 61 54
20436079 2010
2
TNF-alpha-induced aquaporin 9 in synoviocytes from patients with OA and RA. 54 61
20181673 2010
3
Haem oxygenase-1 down-regulates high mobility group box 1 and matrix metalloproteinases in osteoarthritic synoviocytes. 54 61
20110250 2010
4
Expression of aquaporin 1 (AQP1) in human synovitis. 61 54
20149606 2010
5
Immunologic rheumatic disorders. 61 54
20176259 2010
6
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. 54 61
20181277 2010
7
Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. 61 54
19565512 2009
8
Interleukin-6 as a key player in systemic inflammation and joint destruction. 54 61
19189867 2009
9
Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. 54 61
19333931 2009
10
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. 54 61
19883500 2009
11
[Content of C-reactive protein, interleukin-1, interleukin-6 and interleukin-1 receptor antagonist in the blood of patients with early osteoarthrosis of the knee joints]. 61 54
19663194 2009
12
Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging. 54 61
18762862 2009
13
Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. 54 61
18975340 2008
14
Association of body fat with C-reactive protein in rheumatoid arthritis. 61 54
18759279 2008
15
Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? 54 61
18234715 2008
16
Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. 61 54
18578976 2008
17
Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. 61 54
17976692 2008
18
Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. 61 54
18310134 2008
19
Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. 61 54
18565244 2008
20
Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. 54 61
18311806 2008
21
The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. 54 61
18311801 2008
22
Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study. 54 61
18346273 2008
23
[Cartilage oligomeric matrix protein, a possible marker of synovitis in early knee joint osteoarthrosis]. 61 54
19177799 2008
24
Anti-inflammatory activity of chondroitin sulfate. 61 54
18667340 2008
25
Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling. 54 61
18582368 2008
26
Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis. 61 54
17918786 2007
27
Expression of receptor activator of nuclear factor-kappaB ligand in synovial tissue: comparison with degradation of articular cartilage in temporomandibular joint disorders. 61 54
17560137 2007
28
[Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein]. 61 54
17642234 2007
29
Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. 54 61
17425385 2007
30
Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. 61 54
17289161 2007
31
Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. 54 61
17397533 2007
32
Comparison of taurine chloramine and taurine bromamine effects on rheumatoid arthritis synoviocytes. 54 61
16868648 2007
33
Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr observational MRI and NC scintigraphy study. 54 61
16670155 2006
34
Inflammation-induced bone loss: can it be prevented? 61 54
17288976 2006
35
Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac. 54 61
16901276 2006
36
Pathogenesis of spondyloarthritis: insights from synovial membrane studies. 54 61
16839506 2006
37
Anti-TNF and sex hormones. 54 61
16855166 2006
38
The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis. 54 61
16891219 2006
39
Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis? 54 61
16205926 2006
40
The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. 61 54
17177994 2006
41
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 61 54
16542506 2006
42
Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. 54 61
16282041 2005
43
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. 61 54
16329106 2005
44
Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis. 61 54
15672235 2005
45
Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis. 54 61
15843449 2005
46
Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. 54 61
16076882 2005
47
Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. 54 61
16142858 2005
48
Immunoglobulin G from anti-glucose-6-phosphate isomerase antibodies positive patient with rheumatoid arthritis induces synovitis in cynomolgus monkeys. 54 61
16137614 2005
49
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. 61 54
16142748 2005
50
Tumor necrosis factor-alpha increases chemokine gene expression and production in synovial fibroblasts from human temporomandibular joint. 54 61
15946184 2005
Sources

Variations for Synovitis

About this section

ClinVar genetic disease variations for Synovitis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RELN NM_005045.4(RELN):c.7456A>G (p.Ser2486Gly)SNV Pathogenic 684430 7:103163872-103163872 7:103523425-103523425
Sources

Expression for Synovitis

About this section
Search GEO for disease gene expression data for Synovitis.
Sources

Pathways for Synovitis

About this section

Pathways related to Synovitis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.04 VCAM1 TNFSF11 TNF MMP3 MMP1 LTB
2
Integrin Pathway 63
Show member pathways
 13.45 VCAM1 PRG4 MMP3 MMP13 MMP1 ICAM1
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.37 VCAM1 TNFSF11 TNF MMP3 MMP1 LTB
4
Allograft rejection 1 36
Show member pathways
 12.87 TNF IL6 IL1B ICAM1 CXCL8
5
Measles 36
Show member pathways
 12.87 TNF IL6 IL1B IL18 ICAM1 CXCL8
6
Degradation of the extracellular matrix 65
Show member pathways
 12.79 VCAM1 MMP3 MMP13 MMP1 ICAM1 COMP
7
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.78 TNF IL6 IL1RN IL1B IL18 CXCL8
8
NF-kappaB Signaling 4
12.62 VCAM1 TNFSF11 TNF IL1RN IL1B
9
Shigellosis 36
12.41 TNF IL1B IL18 CXCL8
10
Folate Metabolism 1
Show member pathways
 12.39 TNF IL6 IL1B ICAM1 CRP
11
IL-17 Family Signaling Pathways 64
Show member pathways
 12.39 TNF MMP3 MMP13 MMP1 IL6 IL1B
12
Salmonella infection (KEGG) 36
12.37 TNF IL6 IL1B IL18 CXCL8
13
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.36 TNF IL6 IL18 CXCL8
14
Pathogenic Escherichia coli infection 36
12.32 TNF IL6 IL1B IL18 CXCL8
15
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.31 TNF IL6 IL1B IL18 CXCL8
16
NOD-like receptor signaling pathway 36
12.29 TNF IL6 IL1B IL18 CXCL8
17
Tuberculosis 36
12.28 TNF IL6 IL1B IL18
18
Bacterial infections in CF airways 22
Show member pathways
 12.23 TNF IL6 IL1B CXCL8
19
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.23 TNF IL6 IL1RN IL1B CXCL8
20
ECM-receptor interaction 36
Show member pathways
 12.21 VCAM1 RELN ICAM1 COMP COL2A1
21
Fluid shear stress and atherosclerosis 36
12.14 VCAM1 TNF IL1B ICAM1
22
Adhesion 4
12.08 VCAM1 MMP3 MMP13 ICAM1
23
Yersinia infection 36
12.08 TNF IL6 IL1B IL18 CXCL8
24
Spinal Cord Injury 1
12.08 TNF LTB IL6 IL1B ICAM1 CXCL8
25
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.05 TNF IL6 CD68 CD163
26
TNF signaling pathway 36
12.05 VCAM1 TNF MMP3 IL6 IL1B ICAM1
27
IL27-mediated signaling events 1
Show member pathways
 12.01 TNF IL6 IL1B IL18
28
Amoebiasis 36
11.99 TNF IL6 IL1B CXCL8
29
Matrix Metalloproteinases 1
Show member pathways
 11.97 TNF MMP3 MMP13 MMP1
30
AGE-RAGE signaling pathway in diabetic complications 36
11.97 VCAM1 TNF IL6 IL1B ICAM1 CXCL8
31
NF-kappa B signaling pathway 36
11.97 VCAM1 TNFSF11 TNF LTB IL1B ICAM1
32
Glucocorticoid receptor regulatory network 1
11.87 MMP1 IL6 ICAM1 CXCL8
33
Interleukin-4 and 13 signaling 65
11.87 VCAM1 TNF MMP3 MMP1 IL6 IL1B
34
Innate Lymphoid Cells Differentiation 64
11.85 TNF LTB IL1B IL18
35
Pertussis 36
11.83 TNF IL6 IL1B CXCL8
36
TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.82 TNFSF11 TNF LTB
37
LT-BetaR Pathway 63
Show member pathways
 11.82 VCAM1 LTB CXCL8
38
Dendritic Cells Developmental Lineage Pathway 64
11.81 TNF IL6 IL1B CD163
39
Lung fibrosis 1
11.73 TNF IL6 IL1B CXCL8
40
Cell adhesion_ECM remodeling 22
11.73 MMP3 MMP13 MMP1 CXCL8 COL2A1
41
Legionellosis 36
11.69 TNF IL6 IL1B IL18 CXCL8
42
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.66 VCAM1 TNF MMP3 MMP1 IL6 IL1B
43
Hepatitis C and Hepatocellular Carcinoma 1
11.6 MMP1 IL6 CXCL8
44
MSP-RON Signaling 63
11.57 TNF IL1B IL18
45
amb2 Integrin signaling 1
11.57 TNF IL6 ICAM1
46
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.57 TNFSF11 TNF IL6 IL1B
47
Interleukin-10 signaling 65
11.56 TNF IL6 IL1RN IL1B IL18 ICAM1
48
Immune response_Role of integrins in NK cells cytotoxicity 22
11.53 VCAM1 ICAM1 CXCL8
49
IL-10 Pathway 63
11.42 TNF IL6 IL1B
50
African trypanosomiasis 36
11.41 VCAM1 TNF IL6 IL1B IL18 ICAM1
Sources

GO Terms for Synovitis

About this section

Cellular components related to Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNFSF11 TNF RELN PRG4 MMP3 MMP13
2 extracellular matrix GO:0031012 9.63 RELN MMP3 MMP13 MMP1 COMP COL2A1
3 extracellular space GO:0005615 9.53 VCAM1 TNFSF11 TNF RELN MMP3 MMP13

Biological processes related to Synovitis according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10 TNFSF11 TNF IL6 IL1B IL18 CRP
2 leukocyte migration GO:0050900 9.95 TNF MMP1 IL1B ICAM1
3 inflammatory response GO:0006954 9.92 TNF IL6 IL1RN IL1B IL18 CXCL8
4 cellular response to lipopolysaccharide GO:0071222 9.88 TNF IL6 IL1B ICAM1 CXCL8 CD68
5 positive regulation of JNK cascade GO:0046330 9.87 TNFSF11 TNF IL1B
6 cartilage development GO:0051216 9.86 MMP13 COMP COL2A1
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF IL6 IL18
8 cellular response to organic cyclic compound GO:0071407 9.85 TNF IL1B IL18
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNFSF11 TNF IL6 IL1B IL18 ICAM1
10 response to glucocorticoid GO:0051384 9.84 TNF IL6 IL1RN
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.84 TNFSF11 TNF IL6 IL1B
12 extracellular matrix disassembly GO:0022617 9.83 MMP3 MMP13 MMP1
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TNF IL1B IL18
14 positive regulation of T cell proliferation GO:0042102 9.83 VCAM1 IL6 IL1B
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 TNF IL6 IL18
16 positive regulation of interleukin-6 production GO:0032755 9.81 TNF IL6 IL1B
17 immune response GO:0006955 9.81 TNFSF11 TNF PRG4 LTB IL6 IL1RN
18 positive regulation of protein complex assembly GO:0031334 9.8 TNF MMP3 MMP1
19 positive regulation of interferon-gamma production GO:0032729 9.78 TNF IL1B IL18
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 TNF IL1B ICAM1
21 collagen catabolic process GO:0030574 9.77 MMP3 MMP13 MMP1
22 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.75 TNF IL1B COL2A1
23 acute-phase response GO:0006953 9.74 IL6 CRP CD163
24 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 TNF IL1B IL18
25 regulation of neuroinflammatory response GO:0150077 9.69 MMP3 IL6
26 negative regulation of neurogenesis GO:0050768 9.69 TNF IL6 IL1B
27 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.68 IL1B IL18
28 interleukin-6 production GO:0032635 9.68 IL1B IL18
29 growth plate cartilage development GO:0003417 9.67 MMP13 COMP
30 inflammatory response to antigenic stimulus GO:0002437 9.67 IL1RN IL1B CD68
31 regulation of establishment of endothelial barrier GO:1903140 9.66 TNF IL1B
32 positive regulation of glial cell proliferation GO:0060252 9.65 TNF IL6 IL1B
33 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.64 IL6 IL1RN
34 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.63 TNF IL6 ICAM1
35 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.62 IL1B IL18
36 positive regulation of fever generation GO:0031622 9.62 TNF IL1B
37 membrane to membrane docking GO:0022614 9.61 VCAM1 ICAM1
38 negative regulation of lipid storage GO:0010888 9.61 TNF IL6 CRP
39 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
40 positive regulation of neuroinflammatory response GO:0150078 9.56 TNF IL6 IL1B IL18
41 extracellular matrix organization GO:0030198 9.56 VCAM1 TNF MMP3 MMP13 MMP1 ICAM1
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.55 TNF IL1B
43 cytokine-mediated signaling pathway GO:0019221 9.36 VCAM1 TNFSF11 TNF MMP3 MMP1 IL6

Molecular functions related to Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.46 VCAM1 IL1B ICAM1 COMP
2 cytokine activity GO:0005125 9.23 TNFSF11 TNF LTB IL6 IL1RN IL1B
3 tumor necrosis factor receptor binding GO:0005164 9.13 TNFSF11 TNF LTB
Sources

Sources for Synovitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....